Pharmaceutical

Risk adjusted net present value: What is the current valuation of Pfizer’s PF-07264660?

PF-07264660 is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema).

Jul 2, 2024 - 04:00
PF-07264660 is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema).
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Spur Therapeut...

Next Article

Risk adjusted net present value: What is the current valuation of CRISPR Therape...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: In major test for eGenesis, gene-edited pig kidneys kept monkeys alive for more than two years

STAT+: In major test for eGenesis, gene-edited pig kidn...

Oct 12, 2023

Ambulance rides for just $100? Government advisers want major billing fixes

Ambulance rides for just $100? Government advisers want...

Nov 9, 2023

STAT+: A bellwether moment: Once a distant dream, gene therapy for Duchenne nears historic decision

STAT+: A bellwether moment: Once a distant dream, gene ...

Apr 17, 2023